Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01547884 · ClinicalTrials.gov registry record
Effect of Filarial Infection on Immune Responses in Latent Tuberculosis
A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 4,268
- Enrollment target
NCT01547884 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 4,268 participants.
The verdict
NCT01547884 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 4,268 participants
- Enrollment target
Study Summary
Background: \- Lymphatic filariasis is an infection that is caused by small, thread-like worms. It is spread by mosquitoes, and causes fever, chills, and headaches. If untreated, it can also cause elephantiasis, a condition that leads to swelling of the arms, legs, breasts, and scrotum. Treatment can eliminate the worms from the blood and reduce the risk of developing elephantiasis. Researchers want to study people with latent tuberculosis (TB) who may or may not be infected with filariasis. This study will look at the way that people with latent TB fight infection with these worms. Objectives: \- To study how the immune systems of people with latent TB react to filarial infection. Eligibility: \- Individuals between 18 and 65 years of age who have latent TB and may or may not have filarial infection. Design: * Participants will be screened with a physical exam and medical history. They will provide a blood and stool sample to test for infection. * Participants who do not have lymphatic filariasis but have another kind of intestinal worm will be treated for the parasite. This will be their last study visit. * Participants who have latent TB and lymphatic filariasis will be treated with the standard treatment for the disease. They will come back for a second visit 6 months later, and will provide another blood sample.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,268 participants |
| Start Date | 2013-01-01 |
| Est. Completion | 2020-08-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01547884
The ClinicalTrials.gov registry entry for NCT01547884 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 4,268 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01547884 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01547884 about?
NCT01547884 is a clinical study titled "Effect of Filarial Infection on Immune Responses in Latent Tuberculosis". Background: \- Lymphatic filariasis is an infection that is caused by small, thread-like worms. It is spread by mosquitoes, and causes fever, chills, and headaches. If untreated, it can also cause elephantiasis, a condition that leads to swelling of the arms, legs, breasts, and scrotum. Treatment c...
What is the current status of trial NCT01547884?
This trial is currently completed. The enrollment target is 4,268 participants. The study started on 2013-01-01. Estimated completion is 2020-08-07.
Who is sponsoring clinical trial NCT01547884?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.